IL-6 blockades with tocilizumab did not improve short-term survival in advanced pancreatic cancer but showed potential ...

Introduction Duloxetine has previously been reported to be promising in the setting of chemotherapy-induced peripheral neuropathy (CIPN). The aim of this study was to conduct a comprehensive ...

ASCO 2025 overall survival data bolster IMNN-001's potential in advanced ovarian cancer, supported by robust translational results at ESMO Results from OVATION 2 Study reinforce IMNN-001 mechanism of ...

In the DESTINY-Breast09 trial, presented at this year's American Society of Clinical Oncology (ASCO) annual meeting, ...

Robert Holton, a chemist who helped develop an easier, cost-efficient way to produce the blockbuster cancer drug Taxol, paving the way for large-scale production of a medication that has been used ...

Olawaiye noted that the combination is a "well-tolerated regimen and we believe it should be a new standard for platinum-resistant ovarian cancer therapy." Results from the study ...

The oncogene AEG-1 shows promise as a target for managing chemotherapy-induced peripheral neuropathy, according to a recently published study.

Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response  Results, presented simultaneously in oral ...

This phase 1b, single-arm, open-label clinical trial involved adults with advanced or metastatic urothelial carcinoma, progressing during or after platinum-containing chemotherapy, within 12 months of ...

The FIRST/ENGOT-OV44 trial found dostarlimab plus platinum-chemo and niraparib maintenance modestly improved PFS (20.6 vs 19.2 months) in advanced ovarian cancer, with expected safety. Frontline ...